July 10, 2014 12:11 AM ET

Pharmaceuticals

Company Overview of Convergence Pharmaceuticals Limited

Company Overview

Convergence Pharmaceuticals Limited, a biotechnology company, engages in the development of analgesic medicines. Its products include CNV1014802, a small molecule sodium channel blocker for the treatment of neuropathic pain; and CNV2197944, a small molecule calcium channel blocker. Convergence Pharmaceuticals Limited was founded in 2010 and is based in Cambridge, United Kingdom.

Maia Building

Babraham Research Campus

Cambridge,  CB22 3AT

United Kingdom

Founded in 2010

Phone:

44 1223 755 501

Fax:

44 1223 497 114

Key Executives for Convergence Pharmaceuticals Limited

Chief Executive officer and Director
Age: 59
Chief Operating Officer
Head of Chemistry and Pre-Clinical Development
Head of Clinical Operations
Head of Biology
Compensation as of Fiscal Year 2014.

Convergence Pharmaceuticals Limited Key Developments

Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-Breaking Phase II Trigeminal Neuralgia Study

Convergence Pharmaceuticals Holdings Limited announced positive data from the Phase II clinical trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TGN), a very severe form of facial pain. CNV1014802 is a novel small molecule state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel. Following an initial 21 day open-label treatment period with CNV1014802 at a dose of 150mg three times a day (tid), patients who showed a successful response in the final week of the period, defined as a 30% or more reduction in numbers of paroxysms, or severity of paroxysms, relative to the run-in period, were then randomised to a 28 day double-blind treatment period with either CNV1014802 150mg tid or placebo. All patients entering the study had to have a pre-specified number of paroxysmal attacks of at least moderate severity. A total of 67 patients were recruited into the study and 69% of those patients completing the open label period were randomised as clear responders into the double-blind phase of the study. The novel design of this study protocol has been published and is available online. CNV1014802 was well tolerated and the study showed a consistent reduction of pain severity and number of paroxysms in all primary and secondary outcomes. In the primary endpoint of the study there was a treatment failure rate of just 33% for CNV1014802 vs 65% for placebo and a favourable separation from placebo on the Kaplan Meier time to relapse. CNV1014802 showed a 2.3 unit decrease in the NRS scale for pain intensity, 60% reduction in paroxysms vs. 12% in placebo and pain severity dropped by 55% vs. 18% placebo, by the end of the study. There were no serious adverse events related to the drug and the adverse event profile of the drug was similar to placebo in the double blind phase of the study. The full study will be published at the International Association for the Study of Pain (IASP) World Congress of Pain, Buenos Aires in October 2014. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013 and Convergence will utilise these data to design a pivotal clinical study to start in early 2015 with a view to commercialising an orphan drug as soon as possible. This is the first well powered, randomized and placebo controlled clinical trial to demonstrate efficacy of a selective state dependent Nav1.7 inhibitor in a chronic pain indication. This follows years of intensive research and provides huge promise for a better standard of treatment for TGN in the future.

Convergence Pharmaceuticals Plans An IPO

Convergence Pharmaceuticals Limited is preparing for a possible stock market listing. Convergence Pharmaceuticals could raise £50-£100 million in the initial public offering. Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, said that listings in London and New York wre under consideration, with a potential floatation most likely to take place in early 2015. Clive Dix said, “We are now starting to talk to advisers about the state of the FTSE and Nasdaq markets for biotech and are considering seriously floating the company. We'd probably be looking to go out early next year.”

Convergence Pharmaceuticals Limited Presents at 8th Annual BIO Europe Spring 2014, Mar-12-2014 11:45 AM

Convergence Pharmaceuticals Limited Presents at 8th Annual BIO Europe Spring 2014, Mar-12-2014 11:45 AM. Venue: OVAL Lingotto, Turin, Italy.

Similar Private Companies By Industry

Company Name Region
Vita (Europe) Limited Europe
Archimica Ltd. Europe
Lonza Biologics PLC Europe
Mentor Biopolymers Ltd. Europe
Bristol-Myers Squibb Pharmaceuticals Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Convergence Pharmaceuticals Limited, please visit www.convergencepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.